MSC Haifa – Digital Health Demo Day- Photo Credit- Micha Brikman
Eight Israeli startups that graduated from the Startup City Haifa digital health accelerator have developed technologies that will improve healthcare. Some of them are already in negotiations for distribution contracts and global collaborations.
The eight startups chosen to take part in the Startup City Haifa digital health accelerator are:
1. RevitalVision: Vision-training Software for Improving Eyesight (CNS), which is developing a clinically and scientifically proven vision-training software program designed specifically for adult amblyopia, eye diseases, and vision impairments. The non-surgical, FDA-approved technology enhances eyesight neurologically, with claimed efficacy in improving vision in cases of adult amblyopia, which affects 2%-5% of the world’s population.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
2. ApoWiser: Digital Pharmacist Platform for Advice on OTC Medications (SNC), the developer of PharmAssist, an advanced intuitive digital pharmacist counseling platform that interacts with patients wishing to treat themselves for minor ailments with over-the-counter medications. The platform provides personal on-demand assistance 24/7 for online selection and purchase of over-the-counter medication.
3. Sequel.Care Health: Evidence-based Mental Health Platform (CNS), that provides healthcare providers, patients, and peers with virtual, collaborative, evidence-based therapy, enabling proactive treatment to manage and track patients’ recovery. The company’s solution integrates clinicians, psychiatrists, therapists, peers, family, friends, and the patients themselves around a unified treatment plan. The technology collects data signals from caregivers, the person’s smartphone, and wearable sensors. The data is then translated into actionable insights, facilitating the right treatment at the right time.
4. OpenDNA: Precision Genomic Artificial Intelligence for Polygenic Diseases (CNS) is developing an AI platform that combines clinical and genomic data analysis for polygenic diseases. The platform allows healthcare providers and payers to easily apply genomic precision medicine and population genomics approaches. OpenDNA’s first focus is hypertension. The company is extending the platform to other chronic disease states such as diabetes, hypercholesterolemia, cardiometabolic states, and neurologic and psychiatric conditions.
5. Cardiokol: Voice-based Markers for Large-scale Monitoring and Screening of Heart Rhythm Disorders (SNC) Cardiokol is a privately-owned digital telehealth company that develops voice-based markers and methods for monitoring and screening heart rhythm disorders in large at-risk populations. The company utilizes proprietary technology that is implemented in speech platforms such as landlines, smartphones, smart speakers, and voice assistants. Cardiokol offers low-cost, long-term, and user-friendly monitoring solutions, applicable for monitoring at-risk populations of older adults (65+).
6. BoBO: Smart Fitness and Rehabilitation Tools (SNC) that specializes in developing simple and accessible fitness and rehabilitation tools. By turning traditional training products into wireless, integrative, smart training platforms, bo&bo helps motivate people to stick with their training programs, making workouts more challenging, engaging, and fun
7. Sanolla: Smart Diagnostics Solutions (CNS). Sanolla develops medical diagnosis and patient monitoring solutions using patented AI-based infrasound auscultation technology.
8. MDIHealth: Artificial Pharmacology Intelligence Platform (CNS) MDI Health has developed an artificial pharmacology intelligence platform capable of performing multi-dimensional context-based analyses of thousands of pharmacological and patient-specific parameters to autonomously optimize personal medication regimens across the entire population.
The program is led by: NVIDIA Inception Program, Road2, JVP, Margalit Startup City, and the Israel Innovation Authority, in partnership with Super-Pharm, Clalit Health Services, IBM, Philips, U-Bank, the Technion, Haifa University and others.
Innovations include sensor analysis from your mobile phone to prevent psychological deterioration and suicide, early detection of strokes and heart disease through a telephone conversation, an electronic stethoscope that listens to the sounds of the body and detects heart and lung diseases, a dramatic improvement in vision through image processing in the brain, and a bot for over-the-counter medication.
Erel Margalit, chairman of JVP and Margalit Startup City: “The world of health must go through a revolution; from large medical centers to technologies that offer treatment in the community and at home, remotely and in a personalized and precise manner. This is the revolution that Israel needs to lead from here and from Haifa.”
November 24, 2022, Haifa, Israel – The post-COVID era has transformed the global health system, posing significant challenges that call for ground-breaking technological developments. The big problem created an opportunity for the Israeli tech industry and generated significant growth in Israeli innovation in the digital health sector.
While Israel is fast becoming a leading player in digital health, in Haifa – Israel’s northern metropolis – an exciting new ecosystem is under active development, connecting private and public partners: investors, academic and research institutions, multinational corporations, medical institutions and startups. This process aims to lead the next phase in global medicine and develop a new area of international excellence in digital health.
Startup City Haifa is a digital health accelerator that was launched last June to identify promising startups in the field and accelerate their transition to the next level. So far it has successfully brought together leading partners including the NVIDIA Inception Project, Road2, JVP, Margalit Startup City and the Israel Innovation Authority, in partnership with Super-Pharm, Clalit Health Services, IBM, Philips, U-Bank (owned by FIBI), the Takwin Fund, the Technion, Haifa University, Rambam Hospital, Bnai Zion, AWS, Asensus and others.
While over 120 companies submitted applications, only eight were selected to take part. When choosing the companies, emphasis was placed on mature companies with market validation, technological developments at various stages, and activity in the global market.
The Haifa digital health accelerator aims to empower startups to become excellent companies, with a focus on startups in series A funding. Each startup received a program tailored to its technological and business needs, suited to their well-established nature. The companies also received tools, resources, knowledge and expertise, as well as fruitful cooperation with the partners and mentors in the program. This increased the value of the startups and offered opportunities for partnerships between leading Israeli and international corporations in the field.
The participating startups enjoyed significant achievements, including: a pilot program in the USA, closing a funding round, a pilot program in Israel with an extensive network, finalizing distribution contracts, building global collaborations, starting clinical research in Israel and more. In light of the program’s success, registration for the second round of the program has now opened.
